AR080380A1 - Tratamiento de la demencia tipo alzheimer con masitinib - Google Patents
Tratamiento de la demencia tipo alzheimer con masitinibInfo
- Publication number
- AR080380A1 AR080380A1 ARP110100697A ARP110100697A AR080380A1 AR 080380 A1 AR080380 A1 AR 080380A1 AR P110100697 A ARP110100697 A AR P110100697A AR P110100697 A ARP110100697 A AR P110100697A AR 080380 A1 AR080380 A1 AR 080380A1
- Authority
- AR
- Argentina
- Prior art keywords
- alzheimer
- masitinib
- treatment
- neurological
- medicament
- Prior art date
Links
- 239000002139 L01XE22 - Masitinib Substances 0.000 title abstract 4
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004655 masitinib Drugs 0.000 title abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 4
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 208000006011 Stroke Diseases 0.000 abstract 2
- 208000030251 communication disease Diseases 0.000 abstract 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 2
- 230000000926 neurological effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 abstract 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 abstract 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003530 donepezil Drugs 0.000 abstract 1
- 229960003980 galantamine Drugs 0.000 abstract 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 1
- 230000006996 mental state Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 229960004136 rivastigmine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de masitinib, o una de sus sales farmacéuticamente aceptables, en la preparacion de un medicamento para el tratamiento de demencia de tipo Alzheimer, con un régimen de dosificacion apropiado. Reivindicacion 1: Uso de masitinib, o de una de sus sales farmacéuticamente aceptables, y de por lo menos uno de antagonistas del receptor de NMDA (ácido N-metil-D-aspártico) e inhibidores de acetilcolinesterasa, para la preparacion de un medicamento para el tratamiento de la demencia de tipo Alzheimer de acuerdo con la clasificacion del Manual de Diagnostico y Estadística -Revision 4 (criterios del DSM IV), o de acuerdo con los criterios probables de la enfermedad de Alzheimer del Instituto Nacional de Trastornos Neurologicos y Comunicativos y Accidente Cerebrovascular (National Institute of Neurological and Communicative Disorders and Stroke) y la Asociacion de la Enfermedad de Alzheimer y Trastornos Relacionados (Alzheimer's Disease and Related Disorders Association) (NINCDS-ADRDA), en pacientes humanos, donde masitinib debe administrarse diariamente con una dosis inicial de 3,0 a 6,0 +- 1,5 mg/kg/día, opcionalmente, en combinacion con por lo menos uno de antagonistas del receptor de NMDA (ácido N-metil-D-aspártico) e inhibidores de acetilcolinesterasa, y donde dichos pacientes tienen entre 9 y 26, respecto de la miniprueba del estado mental (MMSE). Reivindicacion 14: El uso o el método de acuerdo con cualquiera de las reivindicaciones precedentes, donde el inhibidor de acetilcolinesterasa se selecciona de donepezil, rivastigmina y galantamina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31207910P | 2010-03-09 | 2010-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080380A1 true AR080380A1 (es) | 2012-04-04 |
Family
ID=43754710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100697A AR080380A1 (es) | 2010-03-09 | 2011-03-04 | Tratamiento de la demencia tipo alzheimer con masitinib |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130072474A1 (es) |
| AR (1) | AR080380A1 (es) |
| TW (1) | TW201136928A (es) |
| WO (1) | WO2011110608A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101869741B1 (ko) * | 2013-11-04 | 2018-06-21 | 아주대학교산학협력단 | 마시티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE375342T1 (de) | 2002-08-02 | 2007-10-15 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren |
| JP5568312B2 (ja) | 2007-02-13 | 2014-08-06 | アーべー・シオンス | キナーゼ阻害剤としての２−アミノチアゾール化合物の合成方法 |
-
2011
- 2011-03-04 AR ARP110100697A patent/AR080380A1/es unknown
- 2011-03-07 TW TW100107532A patent/TW201136928A/zh unknown
- 2011-03-09 WO PCT/EP2011/053568 patent/WO2011110608A1/en active Application Filing
- 2011-03-09 US US13/583,482 patent/US20130072474A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130072474A1 (en) | 2013-03-21 |
| TW201136928A (en) | 2011-11-01 |
| WO2011110608A1 (en) | 2011-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| PE20140872A1 (es) | Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| CO2018006358A2 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| NI201100091A (es) | Tratamiento de pirfenidona para pacientes con función hepática atípica. | |
| UY32819A (es) | Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2 | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| TN2015000135A1 (en) | Modified release formulations for oprozomib | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| MX2021002322A (es) | Nuevos metodos. | |
| MX2016009217A (es) | Inmunoterapia basada en liposomas. | |
| AR072951A1 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
| AR088204A1 (es) | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| PE20130147A1 (es) | Combinacion farmaceutica de teobromina y un agente antitusivo no opioide | |
| UY31790A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona | |
| AR080380A1 (es) | Tratamiento de la demencia tipo alzheimer con masitinib | |
| MX2010011193A (es) | Composicion farmaceutica liquida para el tratamiento y prevencion del dolor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |